Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The solvency position, as indicated by the presented metrics, exhibits a generally stable profile with some notable fluctuations over the five-year period. Overall debt levels, relative to equity, capital, and assets, demonstrate moderate changes, while coverage ratios experienced a significant shift in 2023 before recovering somewhat.
- Debt Levels
- The Debt to Equity ratio decreased from 0.87 in 2021 to 0.67 in 2022, suggesting a reduction in financial leverage. However, it increased to 0.93 in 2023 before decreasing to 0.80 in 2024 and rising again to 0.94 in 2025. A similar pattern is observed in the Debt to Equity ratio including operating lease liability, moving from 0.91 to 0.70, then to 0.97, 0.83, and finally 0.96. Debt to Capital ratios, both including and excluding operating lease liabilities, followed a comparable trend, remaining relatively stable around the 0.45-0.49 range, with a dip in 2022 and a slight increase in 2023. Debt to Assets ratios, similarly, showed a slight increase from 0.31 to 0.36 over the period, with a similar fluctuation in 2023. These movements suggest a dynamic capital structure, potentially influenced by financing or investment decisions.
- Leverage Ratios
- Financial Leverage decreased from 2.77 in 2021 to 2.37 in 2022, indicating reduced reliance on debt financing. It then increased to 2.84 in 2023, before decreasing to 2.53 in 2024 and stabilizing at 2.60 in 2025. This mirrors the trends observed in the debt-to-equity ratios, suggesting a consistent relationship between total assets and total debt.
- Coverage Ratios
- Interest Coverage and Fixed Charge Coverage ratios were consistently high from 2021 to 2022, at 18.22 and 13.08 respectively, indicating a strong ability to meet interest and fixed obligations. However, both ratios experienced a substantial decline in 2023, falling to 2.65 and 2.27 respectively. These ratios then recovered significantly in 2024 and 2025, reaching 16.69 and 13.31, and 16.52 and 12.84 respectively. The 2023 decline warrants further investigation, potentially linked to increased debt levels or decreased earnings. The subsequent recovery suggests a return to a more comfortable position regarding fixed charge and interest obligations.
In summary, the company demonstrates a generally manageable debt position, although fluctuations are present. The significant drop and subsequent recovery in coverage ratios in 2023 represent a key area for further scrutiny.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans payable and current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total Merck & Co., Inc. stockholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio exhibits fluctuations over the five-year period. Initially, the ratio decreased, then increased, and stabilized at a level comparable to the beginning of the period. This suggests a dynamic shift in the company’s capital structure.
- Debt to Equity Ratio - Overall Trend
- The debt to equity ratio began at 0.87 in 2021. A notable decrease was observed in 2022, falling to 0.67. The ratio then increased in 2023 to 0.93, decreased slightly to 0.80 in 2024, and concluded at 0.94 in 2025. This indicates an initial deleveraging followed by increased reliance on debt financing, with a slight moderation in 2024 before returning to a similar level in 2025.
Total debt increased from US$33,102 million in 2021 to US$49,339 million in 2025. While there was a decrease in 2022 to US$30,691 million, the overall trend is upward. Total stockholders’ equity also increased over the period, moving from US$38,184 million in 2021 to US$52,606 million in 2025, though it experienced a decrease from 2022 to 2023.
- Debt to Equity Ratio - Key Observations
- The decrease in the ratio in 2022 coincided with a reduction in total debt and an increase in total stockholders’ equity. The subsequent increase in the ratio in 2023 and 2024 occurred despite continued growth in equity, suggesting a more substantial increase in debt. The final increase in 2025 is driven by a larger increase in debt compared to equity.
The fluctuations in the debt to equity ratio suggest the company actively manages its capital structure, potentially in response to investment opportunities, market conditions, or strategic financial decisions. The ratio remains below 1.0 for most of the period, indicating that equity continues to exceed debt, but the trend towards a higher ratio warrants continued monitoring.
Debt to Equity (including Operating Lease Liability)
Merck & Co. Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans payable and current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Current operating lease liability (included in Accrued and other current liabilities) | ||||||
| Noncurrent operating lease liability (included in Other noncurrent liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Merck & Co., Inc. stockholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio, incorporating operating lease liabilities, exhibited fluctuations over the five-year period. Total debt increased from 2021 to 2025, while stockholders’ equity also generally increased, though not consistently. These movements resulted in a dynamic debt to equity ratio.
- Overall Trend
- The debt to equity ratio began at 0.91 in 2021, decreased to a low of 0.70 in 2022, and then generally trended upwards, reaching 0.96 in 2025. This indicates an increasing reliance on debt financing relative to equity financing over the latter part of the analyzed period.
- Year-over-Year Changes
- A significant decrease in the ratio occurred between 2021 and 2022, driven by a larger increase in stockholders’ equity compared to the change in total debt. From 2022 to 2023, the ratio increased substantially from 0.70 to 0.97, primarily due to an increase in total debt and a decrease in stockholders’ equity. The ratio decreased slightly in 2024 to 0.83, as equity grew at a faster rate than debt. Finally, the ratio increased again in 2025 to 0.96, reflecting a more substantial increase in total debt than in stockholders’ equity.
- Debt and Equity Movements
- Total debt demonstrated an initial decrease between 2021 and 2022, followed by increases in subsequent years, culminating in a notable rise between 2024 and 2025. Stockholders’ equity increased from 2021 to 2022, decreased from 2022 to 2023, and then increased again in 2024 and 2025, though the increase from 2024 to 2025 was less pronounced than the increase in total debt.
The observed increases in the debt to equity ratio in 2023, 2024, and 2025 suggest a potential shift in the company’s capital structure towards greater leverage. Continued monitoring of this ratio is warranted to assess the long-term implications for financial risk.
Debt to Capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans payable and current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total Merck & Co., Inc. stockholders’ equity | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio exhibits a fluctuating pattern over the five-year period. Initially, the ratio decreased before stabilizing and then increasing again. Total debt and total capital both increased over the period, but not consistently at the same rate, resulting in the observed ratio variations.
- Debt to Capital Ratio - Overall Trend
- The Debt to Capital ratio began at 0.46 in 2021, decreased to 0.40 in 2022, and then rose to 0.48 in 2023. It subsequently decreased slightly to 0.44 in 2024 before returning to 0.48 in 2025. This indicates a period of deleveraging followed by increased reliance on debt financing.
- Total Debt
- Total debt decreased from US$33,102 million in 2021 to US$30,691 million in 2022. However, it then increased to US$35,055 million in 2023, US$37,111 million in 2024, and reached US$49,339 million in 2025. This represents a substantial increase in debt over the latter part of the observed period.
- Total Capital
- Total capital increased from US$71,286 million in 2021 to US$76,682 million in 2022. It experienced a slight decrease to US$72,636 million in 2023, before increasing to US$83,424 million in 2024 and US$101,945 million in 2025. The growth in total capital appears to accelerate towards the end of the period.
The increase in the Debt to Capital ratio in 2025 suggests that debt financing is growing at a faster rate than equity or other components of total capital. While the ratio remains below 0.50 throughout the period, the upward trend in 2025 warrants further investigation to understand the drivers behind the increased debt levels and their potential implications.
Debt to Capital (including Operating Lease Liability)
Merck & Co. Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans payable and current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Current operating lease liability (included in Accrued and other current liabilities) | ||||||
| Noncurrent operating lease liability (included in Other noncurrent liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Merck & Co., Inc. stockholders’ equity | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio, inclusive of operating lease liabilities, exhibits a fluctuating pattern over the five-year period. Total debt and total capital both increased during the period, but not consistently, resulting in a dynamic ratio.
- Overall Trend
- The Debt to Capital ratio began at 0.48 in 2021, decreased to a low of 0.41 in 2022, and then increased to 0.49 in 2023. It subsequently decreased to 0.45 in 2024 before rising again to 0.49 in 2025. This suggests a moderate level of financial leverage that has remained relatively stable, despite some year-over-year variation.
- Debt Evolution
- Total debt decreased from US$34,631 million in 2021 to US$31,985 million in 2022. However, it then increased over the subsequent three years, reaching US$50,534 million in 2025. This indicates a growing reliance on debt financing in the later part of the observed period.
- Capital Evolution
- Total capital increased from US$72,815 million in 2021 to US$77,976 million in 2022. A slight decrease was observed in 2023 to US$73,849 million, followed by increases in 2024 and 2025, reaching US$103,140 million. The growth in capital suggests an expansion of the company’s funding base, potentially through retained earnings or equity issuance.
- Ratio Dynamics
- The initial decrease in the Debt to Capital ratio in 2022 coincided with a larger percentage decrease in total debt compared to the increase in total capital. The subsequent increases in the ratio in 2023 and 2025 were driven by larger percentage increases in total debt relative to total capital. The ratio’s stabilization around 0.49 in 2023 and 2025 suggests a potential equilibrium point in the company’s capital structure.
The observed fluctuations in both debt and capital levels, and consequently the Debt to Capital ratio, warrant further investigation to understand the underlying drivers of these changes and their implications for the company’s financial risk profile.
Debt to Assets
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans payable and current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio exhibits a generally increasing trend over the observed five-year period. While fluctuations occur, the ratio demonstrates a move from a lower level of leverage to a higher one, particularly in the later years.
- Overall Trend
- The debt-to-assets ratio began at 0.31 in 2021. It decreased to 0.28 in 2022, suggesting a reduction in relative leverage. However, this was followed by an increase to 0.33 in 2023 and a further increase to 0.32 in 2024. The most significant increase occurred between 2024 and 2025, with the ratio reaching 0.36. This indicates a growing proportion of assets financed by debt.
- Year-over-Year Changes
- The largest year-over-year decrease in the ratio was observed between 2021 and 2022, representing a 9.7% decline. Conversely, the most substantial increase occurred between 2024 and 2025, with a 12.5% rise. The increases from 2022 to 2023 and 2023 to 2024 were more moderate, at 17.9% and 3.2% respectively.
- Debt and Asset Movements
- Total debt decreased from US$33,102 million in 2021 to US$30,691 million in 2022, contributing to the initial ratio decline. However, debt levels subsequently increased, reaching US$49,339 million by 2025. Total assets also increased over the period, moving from US$105,694 million in 2021 to US$136,866 million in 2025. The faster rate of increase in total debt compared to total assets in the later years is the primary driver of the rising debt-to-assets ratio.
- Implications
- The increasing debt-to-assets ratio suggests a growing reliance on debt financing. While not inherently negative, this trend warrants further investigation to assess the company’s ability to service its debt obligations and the potential impact on financial flexibility. The magnitude of the increase in 2025 is particularly noteworthy and should be examined in the context of the company’s overall financial strategy and industry benchmarks.
Debt to Assets (including Operating Lease Liability)
Merck & Co. Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans payable and current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Current operating lease liability (included in Accrued and other current liabilities) | ||||||
| Noncurrent operating lease liability (included in Other noncurrent liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt to assets ratio, including operating lease liability, exhibits a generally stable pattern with a slight increasing trend over the observed period. Total debt increased from 2021 to 2025, while total assets also increased, though not consistently at the same rate. This resulted in fluctuations in the ratio, ultimately ending with a higher value in 2025 than in 2021.
- Debt to Assets Ratio Trend
- The ratio began at 0.33 in 2021, decreased to 0.29 in 2022, and then rose to 0.34 in 2023. It remained relatively stable at 0.33 in 2024 before increasing to 0.37 in 2025. This indicates a moderate increase in financial leverage over the five-year period.
- Total Debt Evolution
- Total debt decreased from US$34,631 million in 2021 to US$31,985 million in 2022. Subsequently, it increased to US$36,268 million in 2023 and continued to rise to US$38,270 million in 2024. A significant increase was observed in 2025, reaching US$50,534 million.
- Total Assets Evolution
- Total assets increased from US$105,694 million in 2021 to US$109,160 million in 2022. A slight decrease was noted in 2023, with assets falling to US$106,675 million. Assets then experienced a substantial increase, reaching US$117,106 million in 2024 and further growing to US$136,866 million in 2025.
The increase in the debt to assets ratio in 2025 suggests that the company financed a larger portion of its asset growth with debt during that year. While the ratio remains below 0.40 throughout the period, the upward trend warrants monitoring to assess potential changes in financial risk.
Financial Leverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | ||||||
| Total Merck & Co., Inc. stockholders’ equity | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial leverage of the company, as indicated by the relationship between total assets and total stockholders’ equity, exhibits a fluctuating pattern over the five-year period. Total assets demonstrate an overall increasing trend, while stockholders’ equity also generally increases, though with some variation. The financial leverage ratio itself provides a more nuanced view of the company’s capital structure.
- Financial Leverage
- The financial leverage ratio decreased from 2.77 in 2021 to 2.37 in 2022, suggesting a reduced reliance on debt financing relative to equity. This represents a strengthening of the company’s financial position from a leverage perspective. However, the ratio increased to 2.84 in 2023, indicating a return towards higher leverage. A subsequent decrease to 2.53 in 2024 suggests a renewed effort to moderate leverage, followed by a slight increase to 2.60 in 2025.
Total assets increased from US$105,694 million in 2021 to US$136,866 million in 2025, representing a substantial overall growth. Stockholders’ equity also increased over the period, moving from US$38,184 million in 2021 to US$52,606 million in 2025. The fluctuations in the financial leverage ratio, despite the overall increases in both assets and equity, suggest active management of the company’s capital structure and debt levels.
- Asset and Equity Trends
- While both total assets and total stockholders’ equity generally trend upward, the relative growth rates vary. The period between 2022 and 2023 saw a decrease in total assets, concurrent with a decrease in stockholders’ equity, contributing to the increase in financial leverage during that time. The subsequent increases in both metrics in 2024 and 2025 partially offset this effect, stabilizing the leverage ratio.
The observed patterns indicate that the company actively manages its financial leverage, responding to changes in asset levels and equity positions. The ratio remains relatively stable overall, fluctuating within a range of 2.37 to 2.84, suggesting a deliberate approach to balancing debt and equity financing.
Interest Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Merck & Co., Inc. | ||||||
| Add: Net income attributable to noncontrolling interest | ||||||
| Less: Income from discontinued operations, net of taxes | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio exhibited considerable fluctuation over the five-year period. Initial values were strong, followed by a significant decline, and then a recovery towards the end of the analyzed timeframe.
- Earnings Before Interest and Tax (EBIT)
- EBIT demonstrated an increasing trend from 2021 to 2022, rising from US$14,685 million to US$17,406 million. A substantial decrease was then observed in 2023, with EBIT falling to US$3,035 million. Subsequently, EBIT experienced a strong recovery, increasing to US$21,207 million in 2024 and further to US$22,424 million in 2025.
- Interest Expense
- Interest expense consistently increased throughout the period, albeit at a more moderate pace than the fluctuations in EBIT. It rose from US$806 million in 2021 to US$1,357 million in 2025, indicating a growing cost of borrowing over time.
- Interest Coverage Ratio
- The interest coverage ratio began at a high of 18.22 in 2021 and remained relatively stable at 18.09 in 2022. A dramatic decline occurred in 2023, with the ratio falling to 2.65, reflecting the significant decrease in EBIT combined with rising interest expense. The ratio then rebounded strongly in 2024 to 16.69 and remained at 16.52 in 2025, aligning with the recovery in EBIT. The fluctuations suggest a sensitivity of the company’s ability to cover its interest obligations to changes in operating profitability.
The substantial drop in the interest coverage ratio in 2023 warrants attention, despite the subsequent recovery. While the ratio returned to a healthy level by 2025, the volatility highlights potential risks associated with maintaining consistent profitability. The consistent increase in interest expense also contributes to a potential future strain on earnings if EBIT growth slows.
Fixed Charge Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Merck & Co., Inc. | ||||||
| Add: Net income attributable to noncontrolling interest | ||||||
| Less: Income from discontinued operations, net of taxes | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Operating lease cost | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense | ||||||
| Operating lease cost | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company’s fixed charge coverage exhibited significant fluctuation over the five-year period. While generally strong, a notable decline occurred in 2023 before recovering in subsequent years.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax increased from US$15,028 million in 2021 to US$17,740 million in 2022, representing a substantial gain. However, a dramatic decrease was observed in 2023, falling to US$3,374 million. This metric then rebounded strongly in 2024 to US$21,555 million and continued to rise modestly in 2025, reaching US$22,847 million.
- Fixed Charges
- Fixed charges demonstrated a consistent upward trend throughout the period. Beginning at US$1,149 million in 2021, they increased to US$1,296 million in 2022, US$1,485 million in 2023, US$1,619 million in 2024, and US$1,780 million in 2025. This indicates a growing level of financial obligations requiring periodic payments.
- Fixed Charge Coverage
- The fixed charge coverage ratio was robust in the initial years, standing at 13.08 in 2021 and 13.69 in 2022. The ratio experienced a substantial decline in 2023, dropping to 2.27, coinciding with the significant reduction in earnings before fixed charges and tax. A strong recovery was then seen in 2024, with the ratio rising to 13.31, and it remained high in 2025 at 12.84. The 2023 value represents a considerable weakening in the company’s ability to meet its fixed obligations from its operating earnings, though this appears to be a temporary anomaly given the subsequent recovery.
The volatility in earnings before fixed charges and tax is the primary driver of the fluctuations in the fixed charge coverage ratio. Despite the increasing fixed charges, the company generally maintains a strong capacity to cover these obligations, except for the pronounced dip observed in 2023.